24 percent. That's the mean body weight reduction the top dose tier hit at 48 weeks in the published Phase 2 retatrutide trial. The largest signal any incretin-class compound has produced in the published literature to date.
For comparison, semaglutide tops out around 15 percent in the equivalent trial design, and tirzepatide around 21 percent. Retatrutide cleared both by a wide margin. This piece walks through what the trial actually measured, why three receptors give a bigger signal than two, and the standard research cycle that mirrors the trial protocol.
What does the Retatrutide Phase 2 trial show in detail?
The pivotal Phase 2 retatrutide trial enrolled adults with obesity (without type 2 diabetes) and ran a 48-week dosing window. Four dose tiers (1, 4, 8, and 12 mg weekly) were tested against placebo. Key reported outcomes:
- Mean body weight reduction at the 12 mg dose tier exceeded 24 percent at 48 weeks. The largest published signal for any incretin-class research compound.
- Waist circumference reduction tracked weight reduction in proportion.
- HbA1c, fasting glucose, and lipid panel improvements in line with GLP-1 class.
- GI side effect profile similar in shape to tirzepatide. Slightly higher in frequency at top dose tiers. Mostly mild to moderate. Mostly self-limiting on the slow titration.
- Resting heart rate rose 4 to 10 BPM over baseline at the higher dose tiers, in line with other incretin-class compounds.
Phase 3 trials are ongoing across multiple populations and indications. As of 2026, the compound is not FDA-approved for any human use and is sold only as a research-use compound.
Why three receptors beat two
Retatrutide activates three receptor classes. Each one contributes a distinct slice of the overall metabolic response.
GLP-1 (glucagon-like peptide-1)
Slows gastric emptying so food stays in the stomach longer, which extends satiety. Boosts glucose-dependent insulin release. Acts on appetite-regulating regions of the brain. This is the receptor that defines semaglutide and the first generation of GLP-1 research compounds.
GIP (glucose-dependent insulinotropic polypeptide)
Boosts post-meal insulin release. Supports the body's response to glucose spikes. Appears to play a role in fat metabolism in adipose tissue. The GIP plus GLP-1 dual agonism is the defining feature of tirzepatide.
Glucagon
Traditionally associated with raising blood glucose by pushing liver glucose output. But chronic glucagon agonism at moderate intensity also drives energy expenditure: higher resting metabolic rate, more lipid oxidation in liver and brown adipose tissue. This is the new receptor class retatrutide adds and the leading hypothesis for the larger weight signal versus tirzepatide.
Combined effect: appetite drops (fewer calories in), insulin response improves (better glucose handling), and resting energy expenditure trends up (more calories out). All three working together produce the published Phase 2 signal.
What is the standard Retatrutide research cycle structure?
Research community converges on a 40 to 52 week cycle with slow titration that mirrors the Phase 2 trial design.
| Weeks | Weekly dose | Phase |
|---|---|---|
| 1 to 4 | 2 mg | GI adaptation |
| 5 to 8 | 4 mg | First weight signal |
| 9 to 12 | 6 mg | Plateau pass-through |
| 13 to 16 | 8 mg | Heart rate may rise 4 to 8 BPM |
| 17 to 40 | 10 mg (or 8 mg) | Long maintenance window |
| 41 onward | 10 to 12 mg | Push or hold per target |
The 4-week-per-step titration is the lever that keeps GI side effects manageable. Researchers who compress to 2-week steps almost always have to drop back and restart at a lower dose.
What are the Retatrutide side effects from the trial data?
- Nausea and vomiting, most common in the first 1 to 2 weeks of each dose step. Smaller meals, low-fat choices on injection day, slow titration.
- Lower appetite, the mechanism. Eat protein on schedule.
- Constipation or diarrhea, common at dose escalation. Hydration and fiber.
- Elevated heart rate, 4 to 10 BPM over baseline. Track via wearable.
- Mild high blood sugar signal at high doses in some non-diabetic researchers, likely from the glucagon part. Monitor fasting glucose and HbA1c at week 12 and 24.
- Liver enzyme rise reported at top dose tiers in trial data. Baseline and midpoint ALT and AST monitoring recommended.
How do you reconstitute and store Retatrutide?
Aion ships retatrutide in 10 mg and 20 mg vials. Standard mix for the 10 mg vial: 2 mL of bac water, giving 5 mg per mL or 50 mcg per insulin syringe unit. Full walk-through in our reconstitution guide.
- Lyophilized, sealed: refrigerated at 2 to 8 C, stable for months
- Lyophilized, long-term: minus 20 C freezer for multi-year storage
- Reconstituted with bac water: refrigerated at 2 to 8 C, 4 to 6 week use window
What researchers track on a retatrutide cycle
- Bodyweight, weekly average
- Waist circumference, monthly
- Resting heart rate, weekly via wearable
- HbA1c, fasting glucose, lipid panel, baseline and at week 12, 24, 40
- Liver enzymes (ALT, AST), baseline and at week 24
- Body composition (DEXA), baseline, midpoint, end
What is the Retatrutide bottom line?
Retatrutide is the largest incretin-class signal in the published research, but it's also the compound with the most demanding titration discipline. The slow ramp isn't optional. The wash-out between cycles isn't optional. The baseline labs aren't optional. With those in place, the published Phase 2 outcomes are reproducible in well-tracked research.
For comparison data on the rest of the class, see /research/tirzepatide (21 percent at 72 weeks) and /research/semaglutide (15 percent at 68 weeks).